Jardin A. Leleux

Jardin A. Leleux

Auto-generated profile, based on publicly available information

Jardin A. Leleux

2seventy bio, Cambridge, MA 02124, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Biomaterials
Verified
Journal Article
Closed access
PPPallab Pradhan
Pallab Pradhan
HQHong Qin
Hong Qin
JLJardin A. Leleux
Jardin A. Leleux
DGDongho Gwak
Dongho Gwak
ISIppei Sakamaki
Ippei Sakamaki
KRKrishnendu Roy
Krishnendu Roy

1 September 2020 in Vaccine
Verified
Journal Article
Closed access
JLJardin A. Leleux
Jardin A. Leleux
TATina C. Albershardt
Tina C. Albershardt
APAndrea J. Parsons
Andrea J. Parsons
JMJan ter Meulen
Jan ter Meulen
PBPeter Berglund
Peter Berglund

2 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJardin A. Leleux
Jardin A. Leleux
TATina C. Albershardt
Tina C. Albershardt
RRRebecca Reeves
Rebecca Reeves
RJReice James
Reice James
JKJordan Krull
Jordan Krull
PBPeter Berglund
Peter Berglund
Systemic interleukin-12 (IL12) anti-tumor therapy is highly potent but has had limited utility in the clinic due to severe toxicity. Here, we present two IL12-expressing vector platforms, both of which can overcome the deficiencies of previous systemic IL12 therapies: 1) an integrating lentiviral vector, and 2) a self-replicating messenger RNA formulated with polyethyleneimine. Intratumoral administration of either IL12 vector platform resulted in recruitment of immune cells, including effector T cells and dendritic cells, and the complete remission of established tumors in multiple murine models. Furthermore, concurrent intratumoral administration of the synthetic TLR4 agonist glucopyranosyl lipid A formulated in a stable emulsion (GLA-SE) induced systemic memory T cell responses that mediated complete protection against tumor rechallenge in all survivor mice (8/8 rechallenged mice), whereas only 2/6 total rechallenged mice treated with intratrumoral IL12 monotherapy rejected the rechallenge. Taken together, expression of vectorized IL12 in combination with a TLR4 agonist represents a varied approach to broaden the applicability of intratumoral immune therapies of solid tumors.

20 February 2025 in Molecular Therapy
Verified
Journal Article
Open access
JLJardin Leleux
Jardin Leleux
JRJillian Rosenberg
Jillian Rosenberg
OSOlmo Sonzogni
Olmo Sonzogni
RWRebecca L. Walker
Rebecca L. Walker
AVAnita Venkitaraman
Anita Venkitaraman
JJJordan Jarjour
Jordan Jarjour
Chimeric antigen receptor (CAR) T cells are effective cancer therapies, particularly in indications with high, stable, and tumor-specific antigen expression. Other settings may require improved targeting sensitivity, controllable targeting selectivity, and/or additional potency enhancements to achieve robust efficacy. Here, we describe a novel receptor architecture called RESET (rapamycin-enabled, switchable endogenous T cell receptor) that combines (1) cell surface antigen targeting, (2) small-molecule regulation, and (3) the signaling proficiency and inherent sensitivity of native T cell receptors. RESET-T cells outperformed both constitutive and drug-regulated CAR-T cells and show hallmarks of TCR activation that suggest improved fidelity to native T cell responses. Pharmacological control then increases safety through toggling T cell activation between active and resting states and may mitigate T cell exhaustion caused by continuous antigen exposure. This convergence of drug-regulated targeting and natural immune receptor signal transduction may better replicate the kinetics and physiology of a classical T cell response and potentiate more successful and safer immunotherapies.